Serum amyloid A (SAA) concentrations in 74 patients with primary Sjögren’s syndrome grouped by the presence of various extraglandular manifestations.
| Characteristic, n yes/no | SAA Concentration, mg/l (IQR) | p* | |
|---|---|---|---|
| Yes | No | ||
| Arthralgia, n = 50/24 | 22.8 (11.6, 60.4) | 28.8 (13.8, 55.3) | 0.560 |
| Raynaud’s phenomenon, n = 42/32 | 26.6 (13.4, 55.2) | 27.9 (10.6, 84.9) | 0.815 |
| Recurrent salivary gland swelling, n = 39/35 | 21.0 (11.7, 55.2) | 36.6 (11.8, 95.7) | 0.555 |
| Myalgia, n = 36/38 | 39.0 (14.4, 95.1) | 20.4 (10.7, 47.8) | 0.049 |
| Arthritis, n = 16/58 | 47.2 (11.5, 146.0) | 23.8 (11.8, 51.8) | 0.215 |
| Purpura, n = 15/59 | 13.1 (10.7, 41.3) | 34.3 (13.5, 81.4) | 0.052 |
| Peripheral or central nervous system symptoms, n = 18/56 | 56.5 (36.2, 231.1) | 18.1 (10.7, 46.0) | < 0.0001 |
| Pleuritis, n = 10/64 | 32.2 (11.0, 189.2) | 23.8 (12.1, 55.2) | 0.477 |
| Pulmonary fibrosis or alveolitis, n = 9/65 | 86.0 (11.3, 182.2) | 23.8 (11.8, 54.7) | 0.234 |
| Lymphadenopathy, n = 8/66 | 15.2 (10.0, 48.3) | 31.1 (12.6, 58.5) | 0.300 |
↵* Mann-Whitney U-test. IQR: interquartile range.